Could This Drug Go Beyond Weight Loss?
We’ve talked about semaglutide before.
You’ve probably heard of it as Ozempic, Wegovy, or Rybelsus.
It started out as a diabetes drug, made headlines for weight loss, and now Big Pharma is positioning it as a one-size-fits-all miracle.
And yes, we’ve covered both sides: the pros (like improved blood sugar and shedding pounds) and the cons (like nausea, gut issues, and the unknowns of long-term use).
The truth is, we’re not here to bash every drug on the market. We’re here to give you all the facts—so you can make informed decisions about your health.
Sometimes a drug is the best choice. Other times? Nature has a better answer.
Either way, you deserve the full story—not the carefully curated version sold to you in a 30-second TV spot.
And the full story on semaglutide just got more interesting.
Two major studies—STRIDE and SOUL—are pushing semaglutide into new territory: heart and circulation health.
In the STRIDE trial, people with type 2 diabetes and Peripheral Artery Disease (PAD) saw real improvements in how far they could walk after just a year of taking weekly semaglutide injections. PAD causes narrowed arteries in the legs, making walking painful and difficult. These patients walked 21% farther than before—compared to only 8% in the placebo group.
Let’s break that down…
That’s a median 26.4-meter improvement over placebo. It may not sound like much, but for someone struggling to walk down the block without discomfort, this can be life-changing.
Even more promising? These gains kept getting better over time, suggesting long-term benefits.
Meanwhile, the SOUL trial tested the oral form of semaglutide in people with type 2 diabetes and either heart disease or kidney disease.
Over nearly four years, those taking the drug had a significantly lower risk of heart attack compared to those on placebo. And while it didn’t reduce the risk of death from heart disease, preventing a heart attack is still a big deal.
Plus, oral semaglutide could be a game-changer for people who are hesitant to take injections.
Before we all jump on the bandwagon, it’s worth taking a breath.
These are industry-funded studies. That doesn’t mean the data is wrong—but it does mean we should approach the results with healthy skepticism. After all, the same industry that brought us “heart-healthy” margarine once told us butter was bad. (We now know margarine was the bigger health risk.)
And yes, semaglutide has side effects. In these studies, the most common were gastrointestinal issues—nausea, vomiting, and diarrhea. Some people had to stop taking the drug entirely. Others may face long-term concerns we haven’t even uncovered yet.
Also, let’s be clear: These benefits were seen in people with type 2 diabetes and existing heart or circulation issues. There’s no evidence (yet) that semaglutide helps people without those conditions.
If you’re one of the millions living with diabetes, PAD, or heart risk, semaglutide might be something to consider—with your doctor’s input. But if you’re looking to prevent these conditions, there’s a much simpler route that doesn’t require a prescription pad.
Here are three things you can do starting today:
- Adopt a Mediterranean-style diet.
Think olive oil, nuts, leafy greens, fish, and legumes. This eating style is clinically proven to reduce heart risk, improve circulation, and help regulate blood sugar—naturally. - Get moving.
Walking just 30 minutes a day can improve vascular health, blood sugar, and mental well-being. You don’t need a gym membership—just a good pair of shoes. - Reduce ultra-processed foods (UPFs).
No food group is the enemy—not butter, not eggs—but UPFs? That’s another story. They’re linked to inflammation, heart disease, and metabolic dysfunction. Ditch the packaged snacks and fast food. Your body will thank you.
Semaglutide may offer real benefits for the right person. But don’t let Big Pharma convince you it’s the only solution. And don’t believe the hype without seeing the whole picture.
As always, our job is to give you honest, unbiased information—no sugar-coating, no scare tactics. Just the facts you need to take control of your health.
To the facts,
Rachel Mace
Managing Editorial Director, e-Alert
with contributions from the research team
Sources:
Lou, N. (2025, March 29). STRIDE: Semaglutide Shows It Has Legs in Peripheral Artery Disease. Medpagetoday.com; MedpageToday. https://www.medpagetoday.com/meetingcoverage/acc/114883
